MOCLOBEMIDE (C005B-454358)

Biochem/physiol Actions

Moclobemide acts as a substrate for cytochrome P450 2C19 (CYP2C19). It also behaves as an inhibitor of cytochrome P450 2D6 (CYP2D6), cytochrome P450 1A2 (CYP1A2 and CYP2C19. Moclobemide is also involved in the increased expression of B-cell lymphoma 2 (BcL-2). It also causes neural stem cell (NSC) differentiation into serotoninergic neuron by extracellular¢‚¬‚‚regulated kinase (ERK) pathway.

Moclobemide is a reversible monoamine oxidase A inhibitor (MAOI); antidepressant. Elimination half-life in humans = 1 -3 hrs; absolute oral bioavailability. Unlike other MAO inhibitors, does not significantly increase blood pressure in humans upon combination with tyramine.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

UPC:

51291803

Condition:

New

Weight:

1.00 Ounces

HazmatClass:

No

Quantity:

50

Unit of Measurement:

MG

MPN:

M3071-50MG

CAS:

71320-77-9